In another newly added risk factor, Pfizer discusses the challenge of obtaining and maintaining regulatory approval for pharmaceutical products. It states that additional studies may be required for the FDA to grant marketing authorization or approval for its products. For example, the FDA requires Ffizer to complete certain post-marketing studies for its COVID-19 vaccine Comirnaty by 2024.